サクビトリル/ バルサタン治療後の左心房機能改善の患者に対する最適な維持戦略

Yoonjee Park¹, Minjung Bak^2,3, Heayoung Shin²

¹Department of Cardiology, Bucheon Sejong Hospital, 28, Bucheon-si 14754, Republic of Korea.

|August 28, 2025

まとめ

サクビトリル/ バルサタン (S/ V) の投与を維持するか,レニン- 血管新生系阻害剤 (RASB) に切り替えることは,改善されたエジェクション分数 (HFimpEF) による心不全の患者にとって極めて重要です. 両方の治療を中止すると,心不全の再発のリスクが著しく増加します.

科学分野:

心臓病科
薬理学について

背景:

心不全 (HF) の左心室放出分数 (LVEF) の改善後の最適な薬理学的管理は十分に確立されていません.
HFと改善されたEF (HFimpEF) の患者は,特定の治療戦略を必要とする増加する集団を表しています.

研究の目的:

サクビトリル/ バルサタン (S/ V) の維持とレニン- 血管新生系阻害剤 (RASB) への移行によるHFimpEF患者における臨床結果の比較.
この患者群のHF再発に対するS/ VとRASBの中止の影響を評価する.

主な方法:

S/ V治療後に回復したLVEF (≥40%) を有する354人の患者の遡及分析.
患者は,継続したS/ V (n=294),RASBに切り替えられた (n=47),または両方の治療を中止した (n=13) グループに分けられた.
主要エンドポイント:HF再発 (NT-proBNPの2倍増加>400 pg/dL);二次エンドポイント:NT-proBNPレベルの変化.

主要な成果:

S/V メンテナンスと RASB スイッチグループ間の HF 再発または NT-proBNP レベルに有意な差はありません.
S/ VとRASBの両方の中止は,維持群 (10. 6% - 16. 3%; p=0. 001) と比較して,HF再発率 (53. 8%) が著しく高かった.
両方の治療を中止したグループでは,NT-proBNP濃度がより顕著に増加した.

結論:

HFimpEF患者の寛解を維持するための安全な戦略は,S/ Vを別のRASBに置き換えることです.
HFimpEFでのガイドラインに準じたすべての治療を中止すると,再発のリスクが著しく上昇します.
これらの発見を確認し,長期的な管理を最適化するために将来的な研究が必要です.

キーワード:

N-ターミナルプロホルモンB型ナトリウレチンペプチド射出分数心不全サクビトリル/バルサタン

さらに関連する動画

12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.4K

関連する概念動画

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

505

01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...

01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

関連する実験動画